The use of data from the real world to address clinical and policy-relevant questions that
cannot be answered using data from clinical trials is garnering increased interest. Indeed …

Abstract Background Dermatologic adverse events (AEs) are some of the most frequently
observed toxicities of immune-checkpoint inhibitor therapy, but they have received little …

Importance The randomized clinical trial (RCT) in oncology has evolved since its
widespread adoption in the 1970s. In recent years, concerns have emerged regarding the …

Adverse drug reactions (ADRs) are unwanted drug effects that have considerable economic
as well as clinical costs as they often lead to hospital admission, prolongation of hospital …

Recent reports have highlighted the distinct roles and occasional tension between
randomised controlled trials (RCTs) and population-based observational research (Concato …

Background Docetaxel plus prednisone is standard first-line chemotherapy for men with
metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion …

Background There are limited data about the quality of immune-related adverse event (irAE)
reporting in immune checkpoint inhibitor (ICI) clinical trial publications. Methods A …

Cancer treatment should allow patients to live better or longer lives, and ideally, both. Trial
endpoints should show clinically meaningful improvements in patient survival or quality of …

The introduction of small-molecule tyrosine kinase inhibitors (TKIs) in clinical oncology has
transformed the treatment of certain forms of cancers. As of 31 March 2013, 18 such agents …

Background: The tyrosine kinase inhibitor ponatinib is the only treatment option for chronic
myelogenous leukemia patients with T315I (gatekeeper) mutation. Pharmacovigilance …